Search


	Podcast:		The Bio Report
	Episode:		The Search for Better Obesity Treatments
	Category:		Business
	Duration:		00:37:51
	Publish Date:		2025-07-02 07:00:00
	Description:		Despite the market success of GLP-1 agonists to treat obesity, many patients suffer side effects such as nausea, diarrhea, and vomiting. These medicines also cause significant loss of muscle mass. And when someone discontinues use, they often regain the weight they lost. Skye Biosciences is developing nimacimab, an experimental therapy that has the potential to induce weight loss by inhibiting the CB1 receptor. Because of its different target, it may be able to be used in conjunction with GLP-1 agonists and lower the dose of those drugs to make them more tolerable, or combined with other therapeutic approaches. We spoke to Punhit Dhillon, president and CEO of Skye Biosciences, about CB1 as a target for treating obesity, its experimental therapy nimacimab, and the potential to combine it with GLP-1 agonists and other therapeutic approaches.
	Total Play:		0

Some more Podcasts by Levine Media Group

600+ Episodes

The Bio Repo ..